

PRESS RELEASE

innate pharma

INNATE PHARMA CLINICAL DATA FEATURED AS ORAL PRESENTATIONS AT TWO MAJOR UPCOMING ONCOLOGY CONFERENCES

- ***Late-breaking abstract and oral presentation on clinical and translational biomarker results from the combination of monalizumab and cetuximab in R/M SCCHN at the SITC 2018 Annual Meeting***
- ***Oral presentation of updated data from Phase I of IPH4102 in patients with relapsed/refractory Sézary Syndrome at the ASH 2018 Annual Meeting***

Marseille, France, November 2, 2018, 07:00 AM CET

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 – IPH) today announced that new data from ongoing clinical trials evaluating monalizumab, partnered with AstraZeneca/MedImmune, and first-in-class antibody, IPH4102, will be presented at the SITC* 2018 Annual Meeting in Washington D.C., USA, November 7-11, 2018 and at ASH† 2018 Annual Meeting in San Diego, USA, December 1-4, 2018, respectively.

SITC 2018:


- Title: monalizumab in combination with cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): clinical and translational biomarker results
- Date and time: November 11, 2018, 9:05 am
- Session: Clinical Trials Session 302
- Presenter: Roger Cohen, Principal Investigator and Prof. of Medicine at the Hospital of the University of Pennsylvania
- Location: 202 AB, Walter E. Washington Convention Center, Washington, D.C., USA

ASH 2018:

- Title: IPH4102; an anti-KIR3DL2 monoclonal antibody in refractory Sézary Syndrome: Results from a multicenter phase 1 trial
- Date and time: December 3, 2018, 11:45 am
- Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Immunotherapy and Targeted Strategies.
- Presenter: Martine Bagot, Principal Investigator and Head of the Dermatology Department at the Saint-Louis Hospital, Paris, France
- Location: San Diego Convention Center, Room 6F, San Diego, USA

* Society for Immunotherapy of Cancer

† American Society of Hematology



PRESS RELEASE

innate pharma

Innate Pharma is also taking part in many other scientific congresses, listed below:

- 13th Annual Meeting of Chinese Society for Immunology, Shanghai, China, from November 7 to November 11, 2018
- PEGS Europe 2018, Lisbon, Portugal, from November 12 to November 16, 2018
- 4th ICI Europe Summit, Berlin, Germany, from November 27 to November 29, 2018
- 3rd International Conference on Innate Lymphoid Cells, Tokyo, Japan, from November 29 to December 1st, 2018

For the full schedule of each event, please visit the "[Events](#)" section on Innate Pharma's website.

About Innate Pharma:

Innate Pharma S.A. is a fully integrated oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma's commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma's broad pipeline of antibodies includes several first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a landmark and multi-products partnership with AstraZeneca/MedImmune.

Based in Marseille, France, Innate Pharma is listed on Euronext Paris.


Learn more about Innate Pharma at www.innate-pharma.com.

Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH
LEI	9695002Y8420ZB8HJE29

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual



PRESS RELEASE

innate pharma

results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website (www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors

Innate Pharma

Dr. Markus Metzger / Danielle Spangler /
Jérôme Marino

Tel.: +33 (0)4 30 30 30 30

investors@innate-pharma.com

International Media

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson

Tel.: +44 (0)20 3709 5700

InnatePharma@consilium-comms.com

French Media

ATCG Press

Marie Puvieux

Mob: +33 (0)6 10 54 36 72

presse@atcg-partners.com